Date: 2021/04/30
Your Name: Xiangyu Mao
Manuscript Title: Regulation of dynamin-related protein 1 (DRP1) levels modulates myoblast atrophy induced by C26
colon cancer-conditioned medium
Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	_V_None	
3	Royalties or licenses	_V_None	
4	Consulting fees	_V_None	

5	5 Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	_V_None	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	_V_None	
8	Patents planned, issued or pending	_V_None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	
11	Stock or stock options	<b>/_</b> None	
12	Receipt of equipment, materials, drugs, medical	None	
12	writing, gifts or other services	Constant Characher	Leathing anytherize of a DNA and surgers D224
13	Other financial or non- financial interests	Genechem, Shanghai, China	lentivirus synthesis of si-RNA and express DRP1
		Genewiz, Suzhou, China	transcriptome sequencing

We declare that vectors with siRNAs targeting DRP1 and a negative control siRNA were obtained from GeneChem Inc (Shanghai, China), and the processes of sequencing and analysis were carried out by GENEWIZ (Suzhou, China); there is no professional or other personal interest in services from Genechem, Shanghai, China and Genewiz, Suzhou, China that could be construed as influencing the position presented in the manuscript. For other people or organizations, I have no conflicts of interest to declare.

Please place an "X" next to the following statement to indicate your agreement:

Date: 2021/04/30	
Your Name: Qingyang Meng	
Manuscript Title: Regulation of dynamin-related protein 1 (DRP1) levels modulates myoblast atrophy induced by C2	6
colon cancer-conditioned medium	
Manuscript number (if known):	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as	Specifications/Comments (e.g., if payments were made to you or to your institution)
		needed) Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	_V_None	
3	Royalties or licenses	None	
4	Consulting fees	_V_None	

5	Payment or honoraria for	✓ None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	_ <b>√_</b> None	
	testimony		
7			
7	Support for attending meetings and/or travel	_ <b>√_</b> None	
8	Patents planned, issued or	_✔_None	
	pending		
9	Participation on a Data	_ <b>√_</b> None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	_ <b>√_</b> None	
	in other board, society,		
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	✓ None	
12	Receipt of equipment,	✓ None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	Genechem, Shanghai,	lentivirus synthesis of si-RNA and express DRP1
	financial interests	China	
		Genewiz, Suzhou, China	transcriptome sequencing

We declare that vectors with siRNAs targeting DRP1 and a negative control siRNA were obtained from GeneChem Inc (Shanghai, China), and the processes of sequencing and analysis were carried out by GENEWIZ (Suzhou, China); there is no professional or other personal interest in services from Genechem, Shanghai, China and Genewiz, Suzhou, China that could be construed as influencing the position presented in the manuscript. For other people or organizations, I have no conflicts of interest to declare.

Please place an "X" next to the following statement to indicate your agreement:

Date: 2021/04/30
Your Name: Jun Han
Manuscript Title: Regulation of dynamin-related protein 1 (DRP1) levels modulates myoblast atrophy induced by C26
colon cancer-conditioned medium
Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
	T	Time frame: Since the initial	planning of the work
1	All support for the present	_✔_None	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	_✔_None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	_✔_None	
4	Consulting fees	_✔_None	

5	Payment or honoraria for	✓ None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
6	educational events Payment for expert	✓ None	
0	testimony		
	testimony		
7	Support for attending	✓ None	
	meetings and/or travel		
8	Patents planned, issued or	_ <b>√_</b> None	
	pending		
9	Participation on a Data	_ <b>√_</b> None	
	Safety Monitoring Board or Advisory Board		
10	Leadership or fiduciary role	✓ None	
10	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	_√_None	
12			
12	Receipt of equipment, materials, drugs, medical	None	
	writing, gifts or other		
	services		
13	Other financial or non-	Genechem, Shanghai,	lentivirus synthesis of si-RNA and express DRP1
	financial interests	China	
		Genewiz, Suzhou, China	transcriptome sequencing

We declare that vectors with siRNAs targeting DRP1 and a negative control siRNA were obtained from GeneChem Inc (Shanghai, China), and the processes of sequencing and analysis were carried out by GENEWIZ (Suzhou, China); there is no professional or other personal interest in services from Genechem, Shanghai, China and Genewiz, Suzhou, China that could be construed as influencing the position presented in the manuscript. For other people or organizations, I have no conflicts of interest to declare.

Please place an "X" next to the following statement to indicate your agreement:

Date: 2021/04/30
Your Name: Lei Shen
Manuscript Title: Regulation of dynamin-related protein 1 (DRP1) levels modulates myoblast atrophy induced by C26
colon cancer-conditioned medium
Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as	Specifications/Comments (e.g., if payments were made to you or to your institution)
		needed) Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	_V_None	
3	Royalties or licenses	None	
4	Consulting fees	_V_None	

5	,	_✔_None	
	lectures, presentations,		
	speakers bureaus, manuscript writing or		
	educational events		
6	Payment for expert	_✔_None	
	testimony		
7	Support for attending	✓ None	
'	meetings and/or travel		
8	Patents planned, issued or	_ <b>√_</b> None	
	pending		
9	Participation on a Data	✓ None	
5	Safety Monitoring Board or Advisory Board		
10	<ul> <li>Leadership or fiduciary role in other board, society, committee or advocacy</li> </ul>	_✔_None	
	group, paid or unpaid		
11	Stock or stock options	_ <b>√_</b> None	
12	Descint of emissions		
12	Receipt of equipment, materials, drugs, medical	_ <b>√_</b> None	
	writing, gifts or other	<u> </u>	
	services		
13	Other financial or non- financial interests	Genechem, Shanghai, China	lentivirus synthesis of si-RNA and express DRP1
		Genewiz, Suzhou, China	transcriptome sequencing

We declare that vectors with siRNAs targeting DRP1 and a negative control siRNA were obtained from GeneChem Inc (Shanghai, China), and the processes of sequencing and analysis were carried out by GENEWIZ (Suzhou, China); there is no professional or other personal interest in services from Genechem, Shanghai, China and Genewiz, Suzhou, China that could be construed as influencing the position presented in the manuscript. For other people or organizations, I have no conflicts of interest to declare.

Please place an "X" next to the following statement to indicate your agreement:

Date: 2021/04/30
Your Name: Xiangyu Sui
Manuscript Title: Regulation of dynamin-related protein 1 (DRP1) levels modulates myoblast atrophy induced by C26
colon cancer-conditioned medium
Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
	1	Time frame: Since the initial	planning of the work	
1	All support for the present	_ <b>√_</b> None		
	manuscript (e.g., funding,			
	provision of study materials,			
	medical writing, article			
	processing charges, etc.)			
	No time limit for this item.			
	Time frame: past 36 months			
2	Grants or contracts from	_✔_None		
	any entity (if not indicated			
	in item #1 above).			
3	Royalties or licenses	_√_None		
4	Consulting fees	_✔_None		

5	Payment or honoraria for	_✔_None	
	lectures, presentations,		
	speakers bureaus, manuscript writing or		
	educational events		
6	Payment for expert	_√_None	
	testimony		
7	Support for attending meetings and/or travel	_ <b>√_</b> None	
8	Patents planned, issued or	_√_None	
	pending		
9	Participation on a Data	✓ None	
9	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	_√_None	
	in other board, society,		
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	✓ None	
12	Receipt of equipment,	_✔_None	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	Genechem, Shanghai,	lentivirus synthesis of si-RNA and express DRP1
	financial interests	China	
		Genewiz, Suzhou, China	transcriptome sequencing

We declare that vectors with siRNAs targeting DRP1 and a negative control siRNA were obtained from GeneChem Inc (Shanghai, China), and the processes of sequencing and analysis were carried out by GENEWIZ (Suzhou, China); there is no professional or other personal interest in services from Genechem, Shanghai, China and Genewiz, Suzhou, China that could be construed as influencing the position presented in the manuscript. For other people or organizations, I have no conflicts of interest to declare.

Please place an "X" next to the following statement to indicate your agreement:

Date: 2021/04/30
Your Name: Yihua Gu
Manuscript Title: Regulation of dynamin-related protein 1 (DRP1) levels modulates myoblast atrophy induced by C26
colon cancer-conditioned medium
Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
	ſ	Time frame: Since the initial	planning of the work
1	All support for the present	_✔_None	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	_✔_None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	_✔_None	
4	Consulting fees	_✔_None	

5	Payment or honoraria for	_✔_None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
6	educational events		
6	Payment for expert	_ <b>√_</b> None	
	testimony		
7	Support for attending	✓ None	
/	meetings and/or travel		
8	Patents planned, issued or	_✔_None	
	pending		
9	Participation on a Data	_ <b>√_</b> None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	_ <b>√_</b> None	
	in other board, society, committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	✓ None	
12	Receipt of equipment,	_√_None	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	Genechem, Shanghai,	lentivirus synthesis of si-RNA and express DRP1
	financial interests	China	
		Genewiz, Suzhou, China	transcriptome sequencing

We declare that vectors with siRNAs targeting DRP1 and a negative control siRNA were obtained from GeneChem Inc (Shanghai, China), and the processes of sequencing and analysis were carried out by GENEWIZ (Suzhou, China); there is no professional or other personal interest in services from Genechem, Shanghai, China and Genewiz, Suzhou, China that could be construed as influencing the position presented in the manuscript. For other people or organizations, I have no conflicts of interest to declare.

Please place an "X" next to the following statement to indicate your agreement:

Date: 2021/04/30
Your Name: Guohao Wu
Manuscript Title: Regulation of dynamin-related protein 1 (DRP1) levels modulates myoblast atrophy induced by C26
colon cancer-conditioned medium
Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
	ſ	Time frame: Since the initial	planning of the work
1	All support for the present	_✔_None	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	_✔_None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	_✔_None	
4	Consulting fees	_✔_None	

5	Payment or honoraria for	_√_None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
6	educational events Payment for expert	✓ None	
0	testimony		
	testimony		
7	Support for attending	_✔_None	
-	meetings and/or travel	_•	
8	Patents planned, issued or	_√_None	
	pending		
9	Participation on a Data	None	
	Safety Monitoring Board or		
10	Advisory Board		
10	Leadership or fiduciary role in other board, society,	_ <b>V</b> _None	
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	_√_None	
12	Receipt of equipment,	<b>√_</b> None	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	Genechem, Shanghai,	lentivirus synthesis of si-RNA and express DRP1
	financial interests	China	
		Genewiz, Suzhou, China	transcriptome sequencing

We declare that vectors with siRNAs targeting DRP1 and a negative control siRNA were obtained from GeneChem Inc (Shanghai, China), and the processes of sequencing and analysis were carried out by GENEWIZ (Suzhou, China); there is no professional or other personal interest in services from Genechem, Shanghai, China and Genewiz, Suzhou, China that could be construed as influencing the position presented in the manuscript. For other people or organizations, I have no conflicts of interest to declare.

Please place an "X" next to the following statement to indicate your agreement: